产品
编 号：F118719
分子式：C11H8FN5
分子量：229.21
分子式：C11H8FN5
分子量：229.21
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1316695-35-8
产品详情
生物活性：
LM10 is a potent inhibitor of tryptophan 2,3-dioxygenase (TDO). Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. LM10 has the potential for the research of cancer diseases.
体内研究：
LM10 (160 mg/kg; p.o.) prevents the growth of TDO-expressing P815 tumor cells and promotes better rejection of control clone P815B cl1, which does not express TDO. LM10 displays a good TDO inhibition (Ki = 5.6 μM) with a competitive inhibition profile.LM10 does not inhibit IDO and has a high solubility and bioavailability without obvious signs of toxicity.The plasma concentration of LM10 after oral administration of 160 mg/kg/day is between 20 and 40 μg/mL (87-175 μM), a concentration about 40 times above the IC50 measured in the cellular assay performed with the physiological concentration of plasma tryptophan.Animal Model:DBA/2 mice (6-8 weeks)
Dosage:160 mg/kg/day
Administration:p.o.
Result:Prevented the growth of TDO-expressing P815 tumor cells and promoted better rejection of control clone P815B cl1, which does not express TDO.
LM10 is a potent inhibitor of tryptophan 2,3-dioxygenase (TDO). Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. LM10 has the potential for the research of cancer diseases.
体内研究：
LM10 (160 mg/kg; p.o.) prevents the growth of TDO-expressing P815 tumor cells and promotes better rejection of control clone P815B cl1, which does not express TDO. LM10 displays a good TDO inhibition (Ki = 5.6 μM) with a competitive inhibition profile.LM10 does not inhibit IDO and has a high solubility and bioavailability without obvious signs of toxicity.The plasma concentration of LM10 after oral administration of 160 mg/kg/day is between 20 and 40 μg/mL (87-175 μM), a concentration about 40 times above the IC50 measured in the cellular assay performed with the physiological concentration of plasma tryptophan.Animal Model:DBA/2 mice (6-8 weeks)
Dosage:160 mg/kg/day
Administration:p.o.
Result:Prevented the growth of TDO-expressing P815 tumor cells and promoted better rejection of control clone P815B cl1, which does not express TDO.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备